Oncology expansion

Quote












Recent history has repeatedly shown that GSK is incapable of capitalizing on real opportunities in the oncology sector.

GSK missed the opportunity 20 years ago when other pharmaceutical companies seized the chance to grow and expand their oncology portfolios. While GSK has intermittently entered the field with little success, the recent announcement of new account positions may give a false impression of growth and potential in this area.

Don’t be misled. With subpar products and recycled talent from underperforming internal divisions, GSK’s oncology efforts are likely to result in another short-lived failure. It's best to avoid GSK's oncology division.
 






anonymous said:
Recent history has repeatedly shown that GSK is incapable of capitalizing on real opportunities in the oncology sector.

GSK missed the opportunity 20 years ago when other pharmaceutical companies seized the chance to grow and expand their oncology portfolios. While GSK has intermittently entered the field with little success, the recent announcement of new account positions may give a false impression of growth and potential in this area.

Don’t be misled. With subpar products and recycled talent from underperforming internal divisions, GSK’s oncology efforts are likely to result in another short-lived failure. It's best to avoid GSK's oncology division.
Click to expand...
Sounds about right.
 


















anonymous said:
the range is 150-230. that might seem attractive however no amount would make it a wise choice, look elsewhere as gsk is a proven loser in oncology.
Click to expand...
It’s a good place to get your feet wet and then move on to a real player in the industry. GSK oncology mgmt it’s among the worst, and I mean very worst, in the industry. This is especially true on the Heme side where it’s a bunch of recycled SK nobody’s.
 






anonymous said:
It’s a good place to get your feet wet and then move on to a real player in the industry. GSK oncology mgmt it’s among the worst, and I mean very worst, in the industry. This is especially true on the Heme side where it’s a bunch of recycled SK nobody’s.
Click to expand...
While gaining experience at GSK could be beneficial for those looking to enhance their credentials for future opportunities, there is a concern that gsk may expect to attract top-tier candidates with established networks in oncology. It may be difficult to find individuals with strong connections who would be interested in this opportunity because of less than stellar products vs competition.
 






























Top Bottom
Back
Quote